4,5,6,7-tetrabromo-2-azabenzimidazole has been researched along with Liposarcoma, Myxoid in 1 studies
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor
Liposarcoma, Myxoid: A liposarcoma containing round mesenchymal cells and a myxoid extracellular matrix in stroma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kinases associated with activation of the atypical nuclear factor-kappaB and the Src pathways are the most active in myxoid liposarcoma in vitro and inhibition of nuclear factor-kappaB pathway activation by inhibiting casein kinase 2 using TBB, of which the effect is enhanced by Src inhibition using dasatinib, offers new potential therapeutic strategies for myxoid liposarcoma patients with advanced disease." | 7.76 | Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. ( Bovée, JV; Bruijn, IH; Hogendoorn, PC; Schrage, YM; Szuhai, K; Willems, SM, 2010) |
| "Kinases associated with activation of the atypical nuclear factor-kappaB and the Src pathways are the most active in myxoid liposarcoma in vitro and inhibition of nuclear factor-kappaB pathway activation by inhibiting casein kinase 2 using TBB, of which the effect is enhanced by Src inhibition using dasatinib, offers new potential therapeutic strategies for myxoid liposarcoma patients with advanced disease." | 3.76 | Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. ( Bovée, JV; Bruijn, IH; Hogendoorn, PC; Schrage, YM; Szuhai, K; Willems, SM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willems, SM | 1 |
| Schrage, YM | 1 |
| Bruijn, IH | 1 |
| Szuhai, K | 1 |
| Hogendoorn, PC | 1 |
| Bovée, JV | 1 |
1 other study available for 4,5,6,7-tetrabromo-2-azabenzimidazole and Liposarcoma, Myxoid
| Article | Year |
|---|---|
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
Topics: Casein Kinase II; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dasatinib; HeLa Cells | 2010 |